We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Remission of Sclerosis After Bone Marrow Transplant

By HospiMedica staff writers
Posted on 20 Jul 2006
Bone marrow cell transplantation can result in sustained remission of severe systemic sclerosis, according to a new study.

Researchers at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) performed allogeneic hematopoietic cell transplantation (HCT) in two patients with diffuse cutaneous systemic sclerosis and lung involvement who did not respond to conventional immunosuppressive treatment.

In the first patient, a 38-year-old woman, there were no complications related to the conditioning regimen and no problems with graft versus host disease (GVHD). More...
At five years after HCT, the patient had almost complete resolution of the scleroderma and marked improvement in physical functioning. Her lung condition also improved. Skin biopsy showed resolution of dermal fibrosis. The second patient, a 31-year-old woman, had skin toxicity probably related to the conditioning regimen and a hypertensive crisis that may have been brought about by use of corticosteroids for GVHD. Despite this, she showed improvement in scleroderma and overall functioning, but 18 months after HCT she presented to a local hospital with overwhelming sepsis and died. Death was secondary to pneumonia, with blood cultures positive for Pseudomonas aeruginosa. The results were reported in the June 2006 issue of Arthritis and Rheumatism

"Although there is a risk, the potential benefit of allogeneic hematopoietic cell transplantation is durable disease remission that may improve quality of life and overall function,” said lead investigator Dr. Richard A. Nash. "This is the first report that the fibrotic changes in the skin associated with systemic sclerosis are reversible.”


Related Links:
Fred Hutchinson Cancer Research Center

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.